Drugs that interact with statins
Pro Research Analysisby 
Searched over 200M research papers
Drug Interactions with Statins: A Comprehensive Overview
Introduction to Statins and Their Use
Statins, also known as hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitors, are widely prescribed for lowering cholesterol and preventing cardiovascular diseases. While generally well-tolerated, statins can cause serious side effects, particularly when interacting with other drugs Hirota2015Corsini2008Kellick2014.
CYP Enzyme Interactions
CYP3A4 Inhibitors
Simvastatin, lovastatin, and atorvastatin are metabolized by the CYP3A4 enzyme. Drugs that inhibit CYP3A4 can significantly increase the plasma concentrations of these statins, leading to heightened risk of myopathy and rhabdomyolysis Hirota2015Balasubramanian2021Palleria2020. Common CYP3A4 inhibitors include certain antifungals, antibiotics, and HIV protease inhibitors .
CYP2C9 and Other CYP Enzymes
Fluvastatin is metabolized by CYP2C9, while pravastatin, rosuvastatin, and pitavastatin are not significantly affected by CYP enzyme inhibition. This makes the latter group less prone to interactions with drugs that inhibit CYP enzymes Hirota2015Balasubramanian2021Palleria2020.
Transporter Proteins
P-glycoprotein and OATP1B1
Statins are also substrates for transporter proteins such as P-glycoprotein (P-gp) and organic anion transporting polypeptides (OATP1B1). Inhibitors of these transporters can elevate statin levels, increasing the risk of muscle toxicity. Almost all statins are affected by OATP1B1 inhibitors, which can lead to increased plasma concentrations and adverse effects Balasubramanian2021Palleria2020Kellick2014.
Specific Drug Interactions
Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors
Recent studies suggest that SGLT2 inhibitors, used for type 2 diabetes, may increase statin toxicity. Although pharmacokinetic studies show no significant changes in statin levels, case reports indicate potential interactions, particularly with canagliflozin .
Colchicine
Colchicine, often prescribed alongside statins for cardiovascular and inflammatory conditions, can interact significantly with statins. Both drugs are substrates of CYP3A4 and P-glycoprotein, leading to increased risk of myopathy and rhabdomyolysis when used together .
Antiviral Protease Inhibitors
HIV and HCV protease inhibitors, particularly those combined with ritonavir or cobicistat, are potent CYP3A inhibitors. These can significantly increase the plasma concentrations of simvastatin and lovastatin, making their co-administration contraindicated. Atorvastatin also interacts but to a lesser extent .
Antidepressants
The combination of statins and antidepressants is common due to the co-occurrence of cardiovascular and psychiatric conditions. However, the pharmacokinetic and pharmacodynamic interactions between these two drug classes can lead to adverse effects, necessitating careful management .
Conclusion
Understanding the pharmacokinetic and pharmacodynamic interactions of statins with other drugs is crucial for minimizing adverse effects and ensuring patient safety. Clinicians should be aware of these interactions and consider alternative treatments or dosage adjustments to mitigate risks. Further research and real-world studies are needed to better understand and manage these interactions effectively.
Sources and full results
Most relevant research papers on this topic
HMG-CoA reductase inhibitors (Statins) and their Drug Interactions involving CYP enzymes, P-glycoprotein and OATP Transporters - An Overview.
Statins can interact with other drugs, affecting their effectiveness and toxicity, requiring careful monitoring and prescription management.
Potential drug-drug interaction between sodium-glucose co-transporter 2 inhibitors and statins: pharmacological and clinical evidence
Concomitant use of SGLT2 inhibitors and statins may potentially increase statin toxicity, with canagliflozin showing the highest interaction potential.
Clinically relevant drug interactions between statins and antidepressants
Statins and antidepressants have clinically relevant pharmacokinetic and pharmacodynamic interactions, affecting their use in combination and potentially increasing the risk of adverse events.
An updated review of pharmacokinetic drug interactions and pharmacogenetics of statins
Statin drug interactions and genetic polymorphisms influence their pharmacokinetics, potentially reducing adverse side effects and enhancing drug effectiveness.
Drug interactions with statins
Statins can cause adverse effects like liver enzyme elevation and myopathy when combined with other drugs, especially when interacting with CYP enzymes.
DOI